AC Immune (NASDAQ:ACIU) Stock Passes Below 50-Day Moving Average – Here’s What Happened

Posted by Francis Steltz on Jun 17th, 2026

AC Immune (NASDAQ:ACIU – Get Free Report) passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.80 and traded as low as $2.31. AC Immune shares last traded at $2.37, with a volume of 124,100 shares changing hands.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ACIU shares. Wall Street Zen raised shares of AC Immune from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Jefferies Financial Group reissued a “buy” rating and issued a $7.00 target price on shares of AC Immune in a research note on Friday, March 13th. BTIG Research reissued a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research note on Monday, May 4th. Finally, Weiss Ratings lowered shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $7.50.

Get Our Latest Stock Report on AC Immune

AC Immune Price Performance

The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.02 and a current ratio of 0.87. The stock’s 50 day simple moving average is $2.80 and its two-hundred day simple moving average is $2.97. The firm has a market capitalization of $241.20 million, a PE ratio of -2.89 and a beta of 1.59.

AC Immune (NASDAQ:ACIU – Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.01. The company had revenue of $1.40 million for the quarter, compared to analyst estimates of $0.33 million. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 125.26%. On average, sell-side analysts forecast that AC Immune will post -0.84 EPS for the current year.

Insiders Place Their Bets

In other AC Immune news, CEO Andrea Pfeifer sold 10,000 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $2.79, for a total value of $27,900.00. Following the transaction, the chief executive officer directly owned 3,820,288 shares in the company, valued at $10,658,603.52. The trade was a 0.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by insiders.

Hedge Funds Weigh In On AC Immune

Several institutional investors and hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its holdings in AC Immune by 46.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after purchasing an additional 5,920 shares during the last quarter. EFG International AG acquired a new position in AC Immune in the 4th quarter valued at about $41,000. Private Advisor Group LLC acquired a new position in AC Immune in the 3rd quarter valued at about $48,000. Susquehanna International Group LLP acquired a new position in AC Immune in the 3rd quarter valued at about $63,000. Finally, Sei Investments Co. acquired a new position in AC Immune in the 2nd quarter valued at about $51,000. 51.36% of the stock is currently owned by institutional investors and hedge funds.

About AC Immune

(Get Free Report)

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.